Prot #NS-018-101: A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofib

Project: Research project

Project Details

StatusFinished
Effective start/end date12/13/12 → 12/31/21

Funding

  • Parexel (Prot #NS-018-101 // Prot #NS-018-101)
  • NS Pharma, Inc. (Prot #NS-018-101 // Prot #NS-018-101)